Company profile: Longboard Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of medicines with optimized pharmacology and pharmacokinetics for rare neurological diseases, with a proprietary pipeline including bexicaserin (LP352), an oral, centrally acting 5-HT2C receptor superagonist in development for treating seizures associated with Developmental and Epileptic Encephalopathies, and LP659, an oral S1P receptor modulator for rare neuroinflammatory conditions, plus Longboard Assist patient support services.
Products and services
- Longboard Assist: A patient-services program that delivers disease education, treatment assistance, and clinical study participation support to patients with rare neurological diseases
- LP659: An oral, centrally acting sphingosine-1-phosphate (S1P) receptor modulator in development for treating rare neuroinflammatory conditions
- Bexicaserin (LP352): An oral, centrally acting, next-generation 5-HT2C receptor superagonist in development to treat seizures associated with Developmental and Epileptic Encephalopathies (DEEs)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Longboard Pharmaceuticals
Relmada Therapeutics
HQ: United States
Website
- Description: Provider of central nervous system therapies focused on major depressive disorder, including REL-1017, an NMDA receptor channel blocker in advanced clinical development; the Neuroplastogen program developing esmethadone and psilocybin derivatives to restore impaired neural plasticity without dissociative effects; a metabolic program for modified-release psilocybin for obesity and other metabolic diseases; and an Expanded Access Program for REL-1017.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Relmada Therapeutics company profile →
GeneTx Biotherapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapeutics focused on Angelman syndrome, offering investigational gene and antisense therapies. Pipeline includes GTX-102 for Angelman syndrome (delivering a functional UBE3A gene to the brain), UX055 for CDKL5 Deficiency Disorder, and UX111 for Sanfilippo syndrome type A, with a commitment to clinical trial transparency including trial registration, results publication, and data sharing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneTx Biotherapeutics company profile →
BioElectron
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioElectron company profile →
SyntnX
HQ: United States
Website
- Description: Provider of needle-free drug delivery solutions, discovering and developing novel, long-acting therapeutic products using proprietary Fc-fusion proteins and other engineered ligands that bind to specific Fc receptors. Technologies include the Transceptor drug delivery platform, harnessing the body's natural pathways.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SyntnX company profile →
Global Blood Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for sickle cell disease, including Oxbryta, which increases hemoglobin levels and reduces hemolysis, and voxelotor, an oral, once-daily therapy that increases hemoglobin's affinity for oxygen to reduce red blood cell sickling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Global Blood Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Longboard Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Longboard Pharmaceuticals
2.2 - Growth funds investing in similar companies to Longboard Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Longboard Pharmaceuticals
4.2 - Public trading comparable groups for Longboard Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →